Treatment of chemotherapy-induced nausea and vomiting

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue 6, 2001, Pages 340-345

  Oettle, Helmut ^a   Riess, Hanno ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; ETOPOSIDE; FLUOROURACIL; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; MITOMYCIN; NEUROLEPTIC AGENT; ONDANSETRON; PROCARBAZINE; SEROTONIN ANTAGONIST; STREPTOZOCIN; TROPISETRON; UNINDEXED DRUG;

CHEMOTHERAPY INDUCED EMESIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

ANTIEMETICS; DRUG THERAPY; HUMANS; NAUSEA; RISK FACTORS; VOMITING;

EID: 0035009540     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320000193     Document Type: Review

References (30)

1. 1. Griffin AM, Butow PN, Coates AS, et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7: 189-195
2. 2. Morrow GR, Roscoe JA, Hickok JT, et al (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology 12 [Suppl 4]: 32-37
3. 3. Evers C, Riess H (1992) Neue Aspekte in der Prophylaxe und Therapie von Nausea und Emesis. Z Ärztl Fortbild 86: 847-853
4. 4. Morrow GR (1984) The assessment of nausea and vomiting. Cancer 53: 2267-2278
5. 5. Bountra C, Gale JD, Gardner CJ, et al (1996) Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 53 [Suppl 1]: 102-109
6. 6. Ettinger DS (1995) Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol 22 [Suppl 10]: 6-18
7. 7. Kris MG, Pisters KM, Hinkley L (1994) Delayed emesis following anticancer chemotherapy. Support Care Cancer 2: 297-300
8. 8. Gralla RJ, Clark RA, Kris MG, Tyson LB (1991) Methodology in anti-emetic trials. Eur J Cancer 27: 5-8
9. 9. McVic JG, De Bruijn KM (1992) Methodology of antiemetic trials. Drugs 43: 1-5
10. 10. Bremer K (1994) Individuelle risikoadaptierte antiemetische Stufentherapie. Dtsch Med Wochenschr 119: 598-604
11. 11. Craig JB, Powell BL (1987) The management of nausea and vomiting in clinical oncology. Am J Med Sci 293: 34-44
12. 12. Joss R, Galeazzi R, Bischoff A, et al (1986) The antiemetic activity of high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther 39: 619-624
13. 13. Koo WH, Ang PT (1995) Randomized controlled study to evaluate the role of oral dexamethasone in preventing of chemotherapy-induced delayed emesis. Proc Am Soc Clin Oncol 14:531
14. 14. Ohmatsu H, Eguchi K, Shinkai T, et al (1994) A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Jpn J Cancer Res 85: 1151-1158
15. 15. Roila F, De Angelis V, Contu A, et al (1996) Ondansetron (OND) vs metoclopramide (MTC) both combined with dexamethasone (DEX) in the prevention of cisplatin (CDDP)-induced delayed emesis. Proc Am Soc Clin Oncol 15: 528
16. 16. Roila F, Ballatori E, Angelis V de, Favero A del (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced emesis. J Clin Oncol 16: 2937-2942
17. 17. De Bruijn K (1992) Tropisetron: a review of the clinical experience. Drugs 43 [Suppl 3]: 11-22
18. 18. Milne R, Heel R (1991) Ondansetron. Therapeutic use as an antiemetic. Drugs 41: 574-595
19. 19. Ritter H, Hall S, Mailliard J, et al (1995) A comparative clinical trial of granisetron and Ondansetron in the prophylaxis of cisplatin-induced emesis. Proc Am Soc Clin Oncol 14: 528
20. 20. Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy, [review; 65 refs] Drugs 55: 173-189
21. 21. Jantunen I, Muhonen T, Kataja V, et al (1993) 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur J Cancer 29: 1669-1672
22. 22. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy-and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9: 811-819
23. 23. Schwella N, König V, Schwerdtfeger R, Schmidt-Wolf I, Schmid H, Riess H, Siegert W (1994) Ondansetron for efficient emesis control during total body irradiation. Bone Marrow Transplant 13: 169-171
24. 24. Bregni M, Siena S, Di Nicola M, et al (1991) Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. Eur J Cancer 27: 561-565
25. 25. Sorbe BG, Hogberg T, Glimelius B, et al (1995) Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Anticancer Drugs 6 [Suppl 1]: 31-36
26. 26. Münstedt K, Milch W, Blauth-Eckmeyer E, et al (1995) Delayed emesis and subjective well-being in cisplatinum-containing chemotherapy. Onkologie 18: 23-26
27. 27. Rittenberg CN, Gralla RJ, Lettow LA, et al (1995) New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in a 109 patient trial. Proc Am Soc Clin Oncol 14: 526
28. 28. Morrow GR (1984) Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 2: 1170-1176
29. 29. Lacerda JF, Carmo JA, Pereira ME, et al (1996) A randomized trial of ondansetron, granisetron, and tropisetron in the prophylaxis of acute nausea and vomiting in bone marrow transplantation. Blood 88 [Suppl 1]: 415a
30. 30. Hesketh PJ, Kris MG, Grunberg SM, et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103-109